Introduction {#S1}
============

An extensive involvement of mesenteric fat tissue of the small bowel with chronic non-specific inflammatory disease, first reported by Jura *et al.* in 1924^[@R1]^ was described, detailed, and named as mesenteric panniculitis (MP) by Ogden *et al.* in 1960.^[@R2]^ MP is always discussed with pathological findings concerning its etiology and 3 components of histology, fibrosis, chronic inflammation, and fat necrosis, suggesting various mechanisms of disease (called sclerotic mesenteritis, mesenteric panniculitis, and mesenteric lipodystrophy, respectively).^[@R3]^ Histologically, MP lesion is characterized by the infiltration of mesenteric fat tissue by inflammatory cells, mainly consisting of lymphocytes and plasmacytes, along with a mixture of fat necrosis and fibrosis.^[@R3]^ Although the diagnosis of MP before biopsy is primarily based on guesswork, computed tomography (CT) findings are helpful for cases in which mesentery biopsy is problematic.^[@R4]^ The clinical course of MP is usually benign, and spontaneous remission is quite common without specific treatment.^[@R5]^

The pathogenesis of MP remains obscure and many associated diseases are known, including mechanical stimulation such as surgery or trauma, infections, vascular diseases, and malignant and non-malignant neoplasms.^[@R5]^ The occurrence rate of lymphoma as an underlying disease is 15% or more, and no malignant involvement of the mesentery was diagnosed in almost all cases.^[@R5]^ In a case series of MP accompanied with malignant lymphoma, Kipfer *et al.* (8 cases) suggested that mesenteritis was a non-specific response to underlying lymphoma.^[@R5]^ Other reports introduced MP incidence during the clinical follow-up course of lymphoma. Ogden (2 cases)^[@R6]^ and Perez-Ferriols (1 case)^[@R7]^ both reported on the association of these 2 diseases.

Case Report {#S2}
===========

A 55-year old woman presented with right cervical lymph node swelling in July, 2004, followed by inguinal lymph node swelling a few weeks later. She was admitted to our hospital in August, 2004. The results of the blood and bone marrow examinations performed at that time are shown in [Table 1](#T1){ref-type="table"}. A lymph node biopsy of the inguinal area revealed grade 2 follicular lymphoma. CT images of her neck, thorax and abdomen, and FDG-PET revealed stage IV disease. She was diagnosed as having stage IV lymphoma with femoral bone involvement, as confirmed by femoral MRI. Her follicular lymphoma international prognostic index (FLIPI) was intermediate (stage and lymph-node lesions). IgH-BCL rearrangement (FISH) was detected in her lymph nodes and bone marrow cells, although neither morphological abnormality nor apparent involvement of lymphoma cells were revealed. We did not examine her for IgH-BCL rearrangement of peripheral blood. B symptoms were absent; however, since she complained of bone pain and it was progressive, we decided to treat her with chemotherapy. R-CHOP chemotherapy consisted of rituximab (375 mg/m^2^, day 0), cyclophosphamide (750 mg/m^2^, day 1), doxorubicin (50 mg/m^2^, day 1), vincristine (1.4 mg/m^2^, day 1), and prednisolone (100 mg/kg body weight, day 1--5), injected tri-weekly until 6 courses were completed. At this point only a partial response (PR) was observed through objective radiological evaluations (for nodal masses FDG-PET was negative and more than 50% regression was observed on CT). After R-CHOP, 2 courses at a 3-week interval of the ACES regimen (cytarabine 2,000 mg/m^2^ day 5, carboplatin 100 mg/m^2^ day 1--4, etoposide 80 mg/m^2^ days 1--4, methylprednisolone 500 mg/body days 1--5) were used as salvage chemotherapy, after which her disease was considered to be in CR (IgH-BCL rearrangement in her lymph nodes and bone marrow became negative). At the same time, a contrast-enhanced peritoneal mass appeared on CT imaging ([Figure 1](#F1){ref-type="fig"}A) and FDG-PET ([Figure 1](#F1){ref-type="fig"}B). We identified the pathological etiology of the peritoneal lesion proceeding to the peripheral blood stem cell transplantation (PBSCT) by CT-guided biopsy, which revealed mesenteric panniculitis (MP) not concomitant with the lymphoma lesion ([Figure 1](#F1){ref-type="fig"}C). Her MP did not produce symptoms through her treatment course. However, the bone lesion recurred in June, 2005, when she received PBSCT. She has maintained CR with no progression of the MP mass for more than three years.

Table 1Laboratory data on admission. The profile of the peripheral blood cell count was within the normal range. Biochemical data showed a normal LDH level and no organ disorders. Cytogram of bone marrow revealed no obvious morphological changes and the involvement of lymphoma cells was not detected.Component of blood cell White blood cells9100 /µL (3500∼9100) Granulocytes69% (32∼79) Eosinophils1% (0∼6) Basaophils2% (0∼2) Monocytes3% (0∼8) Lymphocytes25% (18∼59) Red blood cells415×10^4^/µL (376∼500) Hemoglobin12.6 g/dL 11.3∼15.2) Hematocrit37.4% (33.4∼44.9) Platelets23.1×10^4^/µL(13.0∼36.9)Biochemistry Total protein7.7 g/dL (6.7∼8.3) Albumin4.6 g/dL (4.0∼5.0) Total billirubin0.4 mg/dL (0.3∼1.2) Glutamic pyruvic transaminase19 IU/L (5∼40) Lactate dehydrogenase195 IU/L (115∼245) Alkaline phosphatase259 IU/L (115∼359) Blood urea nitrogen15.9 mg/dL (8.0∼22.0) Creatinine0.6 mg/dL (0.47∼0.79) Urine acid3.8 mg/dL (2.5∼7.0) Natrium142 mEq/L (136∼147) Potassium4.1 mEq/L (3.6∼5.0) Chloride106 mEq/L (98∼109)Coagulation Prothrombin time97% (70∼130) Activated partial thromboplastin time28.5 sec (24.3∼36.0) International normalized ratio1.02 (0.85∼1.15) Fibrinogen274 mg/dL (150∼400)Bone marrow Number of nuclear cells9.4 ×10^4^/µL (10∼20) Megakaryocytes43.8×10^4^/µL (50∼150) Myeloid/erythroid ratio2.36 (2∼4) Blasts0.2% (1.0∼1.5) Promyelocytes0.6% (2.0∼6.5)

Figure 1Imaging and pathologic evaluation of mesenteric panniculitis. During treatment and before SCT, we evaluated the clinical course of the mesenteric mass by CT (A) and 18F-FDG-PET (B). (A) Clinical course of mesenteric lesion evaluated by CT imaging. Mesenteric hypertrophy before treatment reduced during chemotherapy (i), after salvage chemotherapy (ii), and before PBSCT (iii). Arrows indicate hypertrophic mesenterium. (B) Clinical course of mesenteric lesion evaluated by FDG-PET. An accumulation positioned at the mesenterium detected by FDG-PET (i) was more intensified after salvage chemotherapy (ii) and did not improve before PBSCT (iii). Arrows indicate an increased accumulation in accordance with the enlarged mesenterium. (C) Pathological findings of biopsied mesenteric mass. Fatty necrosis surrounded by foamy macrophages and reactive lymph adenopathy was characteristic of the mesenterium. Immunohistological staining failed to detect CD20, CD10, CD79a, and bcl-2, with no indications of malignant lymphoma: (i) H-E stain (× 400), (ii) H-E stain (× 1000).

Discussion {#S3}
==========

Mesenteric panniculitis is a lipodystrophy characterized by non-specific inflammatory disease first reported by Ogden *et al.*^[@R2]^ Emory et al. reviewed 84 cases of MP pathologically and documented that a mixed histology of 3 components (fibrosis, chronic inflammation, and fat necrosis) existed in the lesions, which could be classified according to the dominant pathological changes, i.e. mesenteric lipodystrophy (ML) type, mesenteric panniculitis (MP) type, and sclerosing mesenteritis (SM) type. However, not all cases can be definitively categorized in these 3 subtypes because the histologically dominant subtype is often too varied to define as ML, MP, or SM, respectively.^[@R3]^ Due to this pathological variation and the various underlying diseases of MP, the etiology of this disease is thought to be a single pathology with various causes including immunological reactions, malignancies, infection, physical stimulation, or traumatic disorders.

Past retrospective analysis reported that, in general, MP occurs in patients in their 60s (median age of occurrence), has slightly higher incidence in men, is accompanied by abdominal pain, and is often associated with malignant lymphoma.^[@R8],[@R9]^ Generally, isolated MP does not need to be treated.^[@R4]^ Kipfer *et al.* reported that 8 among 53 reviewed cases of MP with malignant lymphoma led to complications related to MP.^[@R5]^ They could find no pathological involvement of lymphoma in the panniculitis lesion in any case. In 3 of the 8 cases, MP existed with malignant lymphoma concomitantly. In 2 other patients, the lymphoma lesion was found two or three months later. Another 3 patients were diagnosed as having malignant lymphoma occurring in a different area from the MP lesion. These findings suggest that MP can precede or proceed to lymphoma. However, no panniculitis has been revealed in lymphoma lesions by biopsy, and no obvious association has been reported until now. In our case, the mesenteric lesion progressed and was detected by FDG-PET imaging during chemotherapy, which reduced to remission the lymphoma lesions (lymph nodes and femoral bone head). This discrepant course made it problematic for physicians to decide on a treatment plan. If we had regarded the mesenteric mass in our patient as refractory lymphoma, we would have had to administer a salvage regimen. If the mesenteric mass had been benign, we could have continued the existing regimen. A biopsy confirmed the remission of her lymphoma and resolved this problem. Autologous PBSCT brought about a durable CR in the patient. The MP lesion regressed after the planned treatments, with no recurrence for three years. Therefore, we recognized that her MP was chemotherapy-related panniculitis, since panniculitis is thought to be brought about by physical or chemical stimulation.^[@R5]^

Although FDG-PET was an effective and powerful tool for the staging, localization, and response assessment of malignant lymphoma, the differential diagnosis for lymphoma lesions with physiological accumulation or inflammatory change is sometimes difficult.^[@R10],[@R11]^ Though FDG-PET/CT fusion imaging is more efficient for diagnosis of the active lymphoma lesion,^[@R11]^ a pathological diagnosis via biopsy is essential for cases in which a false positive is suspected. Zissin *et al.* reviewed 19 oncological patients with MP^[@R12]^ and reported that FDG-PET had high specificity (100%) among 11 FDG-PET-negative subjects and 88% sensitivity (7 out of 8 subjects). We concluded that mesenteric lesions suspected of progressing or recurring with positive uptake with FDG-PET should be diagnosed pathologically even if asymptomatic.
